The results from Pfizer’s two Phase I safety studies for new Alzheimer’s disease compounds showed that the treatment was well tolerated, with no clinical or imaging evidence of vasogenic edema.

The compounds tested were PF-04360365, a humanised anti-amyloid monoclonal antibody, and dimebon combined with donepezil HCl tablets.

A Phase I, single-dose, dose escalation study (0.1 to 10mg/kg) showed that the investigational compound PF-04360365 was well tolerated in all patients. No sign of clinical or imaging evidence of vasogenic edema, and no new microhaemorrhage or encephalitis were reported in the ongoing follow-up period.

Pfizer vice-president and head of medical affairs for the Primary Care Business Steven Romano said that the company has the investigational compound dimebon (latrepirdine) in Phase III testing and two other compounds in Phase II testing.

The data was presented at the Alzheimer’s Association 2009 International Conference on Alzheimer’s Disease (ICAD) in Vienna, Austria.